A new and pricey rare-disease drug that angered many patients — and prompted Sen. Bernie Sanders (I-Vt.) to protest its cost — is showing signs of becoming a hit on Wall Street.

In a call with analysts, Catalyst Pharmaceuticals (CPRX) chief executive Patrick McEnany disclosed that about 250 patients are being treated with Firdapse, which is used to combat Lambert-Easton myasthenic syndrome, or LEMS, and has a list price of $375,000.  He also reported most patients are paying $10 a month, thanks to assistance programs, and payers are responding “better than expected.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy